Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer

Won Tae Kim, Seok Joong Yun, Cheol Park, Isaac Kim, Sung Kwon Moon, Tae Gyun Kwon, Yung Hyun Choi, Wun Jae Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Methylation-induced silencing of PRSS3 has been shown to be significantly associated with invasive bladder cancer, and expression of the C16orf74 gene locus has been shown to correlate positively with PRSS3. The aim of the current study was to evaluate the relationship between C16orf74 expression level and progression in non-muscle invasive bladder cancer (NMIBC). Materials and Methods: C16orf74 mRNA levels were examined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis of 193 tumor specimens from patients with primary NMIBC. Expression data were analyzed in terms of clinical and experimental parameters. Kaplan-Meier curves and multivariate Cox regression models, respectively, were used to determine progression-free survival and to identify independent predictive parameters of progression. Results: Analysis using Kaplan-Meier curves revealed prolonged progression-free survival of high-C16orf74-expressors as compared to low-expressors (p<0.001). Multivariate Cox regression analysis revealed that low C16orf74 mRNA expression levels are a significant risk factor for disease progression in patients with primary NMIBC (HR: 10.042, CI:2.699-37.360, p = 0.001). Conclusions: Decreased expression of C16orf74 correlates significantly with progression in primary NMIBC. C16orf74 expression level represents a potentially useful marker for predicting progression in primary NMIBC patients.

Original languageEnglish (US)
Article numbere15260
JournalPLoS ONE
Volume5
Issue number12
DOIs
StatePublished - Dec 1 2010

Fingerprint

Urinary Bladder Neoplasms
Messenger RNA
Methylation
Polymerase chain reaction
RNA-Directed DNA Polymerase
Regression analysis
Tumors
Genes
Disease-Free Survival
Kaplan-Meier Estimate
Reverse Transcriptase Polymerase Chain Reaction
Proportional Hazards Models
disease course
methylation
Disease Progression
urinary bladder neoplasms
Real-Time Polymerase Chain Reaction
quantitative polymerase chain reaction
regression analysis
risk factors

All Science Journal Classification (ASJC) codes

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Kim, Won Tae ; Yun, Seok Joong ; Park, Cheol ; Kim, Isaac ; Moon, Sung Kwon ; Kwon, Tae Gyun ; Choi, Yung Hyun ; Kim, Wun Jae. / Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer. In: PLoS ONE. 2010 ; Vol. 5, No. 12.
@article{b68c129f20574341ac2b5730f5da0f35,
title = "Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer",
abstract = "Purpose: Methylation-induced silencing of PRSS3 has been shown to be significantly associated with invasive bladder cancer, and expression of the C16orf74 gene locus has been shown to correlate positively with PRSS3. The aim of the current study was to evaluate the relationship between C16orf74 expression level and progression in non-muscle invasive bladder cancer (NMIBC). Materials and Methods: C16orf74 mRNA levels were examined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis of 193 tumor specimens from patients with primary NMIBC. Expression data were analyzed in terms of clinical and experimental parameters. Kaplan-Meier curves and multivariate Cox regression models, respectively, were used to determine progression-free survival and to identify independent predictive parameters of progression. Results: Analysis using Kaplan-Meier curves revealed prolonged progression-free survival of high-C16orf74-expressors as compared to low-expressors (p<0.001). Multivariate Cox regression analysis revealed that low C16orf74 mRNA expression levels are a significant risk factor for disease progression in patients with primary NMIBC (HR: 10.042, CI:2.699-37.360, p = 0.001). Conclusions: Decreased expression of C16orf74 correlates significantly with progression in primary NMIBC. C16orf74 expression level represents a potentially useful marker for predicting progression in primary NMIBC patients.",
author = "Kim, {Won Tae} and Yun, {Seok Joong} and Cheol Park and Isaac Kim and Moon, {Sung Kwon} and Kwon, {Tae Gyun} and Choi, {Yung Hyun} and Kim, {Wun Jae}",
year = "2010",
month = "12",
day = "1",
doi = "https://doi.org/10.1371/journal.pone.0015260",
language = "English (US)",
volume = "5",
journal = "PloS one",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer. / Kim, Won Tae; Yun, Seok Joong; Park, Cheol; Kim, Isaac; Moon, Sung Kwon; Kwon, Tae Gyun; Choi, Yung Hyun; Kim, Wun Jae.

In: PLoS ONE, Vol. 5, No. 12, e15260, 01.12.2010.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer

AU - Kim, Won Tae

AU - Yun, Seok Joong

AU - Park, Cheol

AU - Kim, Isaac

AU - Moon, Sung Kwon

AU - Kwon, Tae Gyun

AU - Choi, Yung Hyun

AU - Kim, Wun Jae

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Purpose: Methylation-induced silencing of PRSS3 has been shown to be significantly associated with invasive bladder cancer, and expression of the C16orf74 gene locus has been shown to correlate positively with PRSS3. The aim of the current study was to evaluate the relationship between C16orf74 expression level and progression in non-muscle invasive bladder cancer (NMIBC). Materials and Methods: C16orf74 mRNA levels were examined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis of 193 tumor specimens from patients with primary NMIBC. Expression data were analyzed in terms of clinical and experimental parameters. Kaplan-Meier curves and multivariate Cox regression models, respectively, were used to determine progression-free survival and to identify independent predictive parameters of progression. Results: Analysis using Kaplan-Meier curves revealed prolonged progression-free survival of high-C16orf74-expressors as compared to low-expressors (p<0.001). Multivariate Cox regression analysis revealed that low C16orf74 mRNA expression levels are a significant risk factor for disease progression in patients with primary NMIBC (HR: 10.042, CI:2.699-37.360, p = 0.001). Conclusions: Decreased expression of C16orf74 correlates significantly with progression in primary NMIBC. C16orf74 expression level represents a potentially useful marker for predicting progression in primary NMIBC patients.

AB - Purpose: Methylation-induced silencing of PRSS3 has been shown to be significantly associated with invasive bladder cancer, and expression of the C16orf74 gene locus has been shown to correlate positively with PRSS3. The aim of the current study was to evaluate the relationship between C16orf74 expression level and progression in non-muscle invasive bladder cancer (NMIBC). Materials and Methods: C16orf74 mRNA levels were examined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis of 193 tumor specimens from patients with primary NMIBC. Expression data were analyzed in terms of clinical and experimental parameters. Kaplan-Meier curves and multivariate Cox regression models, respectively, were used to determine progression-free survival and to identify independent predictive parameters of progression. Results: Analysis using Kaplan-Meier curves revealed prolonged progression-free survival of high-C16orf74-expressors as compared to low-expressors (p<0.001). Multivariate Cox regression analysis revealed that low C16orf74 mRNA expression levels are a significant risk factor for disease progression in patients with primary NMIBC (HR: 10.042, CI:2.699-37.360, p = 0.001). Conclusions: Decreased expression of C16orf74 correlates significantly with progression in primary NMIBC. C16orf74 expression level represents a potentially useful marker for predicting progression in primary NMIBC patients.

UR - http://www.scopus.com/inward/record.url?scp=78650976058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650976058&partnerID=8YFLogxK

U2 - https://doi.org/10.1371/journal.pone.0015260

DO - https://doi.org/10.1371/journal.pone.0015260

M3 - Article

VL - 5

JO - PloS one

JF - PloS one

SN - 1932-6203

IS - 12

M1 - e15260

ER -